07:46 AM EDT, 08/21/2024 (MT Newswires) -- Mark Neumann, EVP, Chief Commercial Officer, on August 16, 2024, sold 18,714 shares in Intra-cellular Therapies ( ITCI ) for $1,405,047. Following the Form 4 filing with the SEC, Neumann has control over a total of 29,700 shares of the company, with 29,700 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/xslF345X03/ownership.xml